In the Claims:

Please amend claims 3-8 and 10-11 as follows. Please add new claims 12 to 20.

1. (Original) A compound of formula (I):



(I)

wherein:

Y is phenyl, optionally substituted with one, two or three substituents;

$R^1$ is selected from hydrogen, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl and halosubstituted$C_{1-6}$ alkyl;

$R^2$ is $(CH_2)_mR^3$ where m is 0 or 1;

or $R^1$ and $R^2$ together with N to which they are attached form an optionally substituted 4- to 8- membered non-aromatic heterocyclyl ring;

$R^3$ is an optionally substituted 4- to 8- membered non-aromatic heterocyclyl group, an optionally substituted $C_{3-8}$ cycloalkyl group, an optionally substituted straight or branched $C_{1-10}$ alkyl, a $C_{5-7}$ cycloalkenyl or $R^5$;

$R^4$ is selected from hydrogen, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, or halosubstituted$C_{1-6}$ alkyl, $COCH_3$, and $SO_2Me$;

$R^5$ is



wherein p is 0, 1 or 2 and X is $CH_2$ or O;

$R^6$ is methyl, chloro or CHxFn wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;

$R^7$ is OH, $C_{1-6}$alkoxy, $NR^{8a}R^{8b}$, $NHCOR^9$, $NHSO_2R^9$, $SOqR^9$;

$R^{8a}$ is H or $C_{1-6}$alkyl;

$R^{8b}$ is H or $C_{1-6}$alkyl;

$R^9$ is $C_{1-6}$alkyl;

q is 0, 1 or 2;

or a pharmaceutically acceptable derivative thereof.

2. (Original) A compound as claimed in claim 1 wherein Y is a substituted phenyl.

3. (Currently Amended) A ~~compound as claimed in claim 1 wherein the~~ compound ~~is~~ of formula (Ia):



(Ia)

~~wherein;~~

wherein;

$R^1$ is selected from hydrogen, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl and halosubstituted$C_{1-6}$ alkyl;

$R^2$ is $(CH_2)_mR^3$ where m is 0 or 1;

or $R^1$ and $R^2$ together with N to which they are attached form a 4- to 8-membered non- aromatic ring selected from azetidinyl, pyrrolidinyl, morpholinyl, piperizinyl, piperidinyl, tetrahydropyridinyl, azapine, oxapine, azacyclooctanyl, azaoxacyclooctanyl and azathiacyclooctanyl any of which can be unsubstituted or substituted by one, two or three substituents selected from $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, a hydroxy group, a cyano group, halo, sulfonyl group, methylsulfonyl, $NR^{8a}R^{8b}$, $NHCOCH_3$, (=O), and -$CONHCH_3$.

$R^3$ is 2- or 3- azetidinyl, oxetanyl, thioxetanyl, thioxetanyl-s-oxide, thioxetanyl-s,s-dioxide, dioxalanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, morpholinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, thiomorpholinyl, thiomorpholinyl-s,s-dioxide, tetrahydropyridinyl, azapine, oxapine, azacyclooctanyl, azaoxacyclooctanyl, azathiacyclooctanyl, oxacylcooctanyl, thiacyclooctanyl, a $C_{3-8}$ cycloalkyl group, a straight or branched $C_{1-10}$ alkyl, a $C_{5-7}$ cycloalkenyl or $R^5$, any of which can be unsubstituted or substituted by one, two or three substituents selected from $C_{1-6}$

alkyl, $C_{1-6}$ alkoxy, a hydroxy group, a cyano group, halo, sulfonyl group, methylsulfonyl, $NR^{8a}R^{8b}$, $NHCOCH_3$, (=O), and $-CONHCH_3$;

$R^{10}$ is selected from $C_{1-6}$ alkyl, halosubstituted$C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, a hydroxy group, a cyano group, halo, a $C_{1-6}$alkyl sulfonyl group, $-CONH_2$, $-NHCOCH_3$, -COOH, halosubstituted$C_{1-6}$ alkoxy, $SC_{1-6}$alkyl and $SO_2NR^{8a}R^{8b}$;

$R^4$ is selected from hydrogen, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, or halosubstituted$C_{1-6}$ alkyl, $COCH_3$, and $SO_2Me$;

$R^5$ is




wherein p is 0, 1 or 2 and X is $CH_2$ or O;

$R^6$ is methyl, chloro or CHxFn wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;

$R^7$ is OH, $C_{1-6}$alkoxy, $NR^{8a}R^{8b}$, $NHCOR^9$, $NHSO_2R^9$, $SOqR^9$;

$R^{8a}$ is H or $C_{1-6}$alkyl;

$R^{8b}$ is H or $C_{1-6}$alkyl;

$R^9$ is $C_{1-6}$alkyl;

q is 0, 1 or 2; and

d is 0, 1, 2 or 3

or a pharmaceutically acceptable derivative thereof.

4. (Currently Amended) A compound as claimed in claim 1 ~~any one of claims 1 to 3~~ wherein $R^4$ is $C_{1-6}$alkyl or hydrogen.

5 . (Currently Amended) A compound as claimed in claim 1 ~~any one of claims 1 to 4~~ wherein $R^6$ is $CF_3$.

6. (Currently Amended) A compound as claimed in claim 1 ~~or 3~~ selected from any one of Examples 1 to 265 or a pharmaceutically acceptable derivative thereof.

7. (Currently Amended) A compound as claimed in claim 1 in ~~any one of claims 1 to 6~~ nanoparticulate form.

8. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 ~~any one of claims 1 to 7 or a pharmaceutically acceptable derivative thereof~~.

9. (Original) A pharmaceutical composition as claimed in claim 8 further comprising a pharmaceutical carrier or diluent thereof.

10. (Currently Amended) A method of treating an ~~a human or~~ animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound ~~of formula (I)~~ as claimed in claim 1 ~~any one of claims 1 to 7 or a pharmaceutically acceptable derivative thereof~~.

11. (Currently Amended) A method of treatment as claimed in claim 10 wherein the condition is an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis ~~or renal disorder~~.

12. (New) The method as claimed in claim 10, wherein said animal is a human.

13. (New) The method as claimed in claim 11 wherein the pain is selected from inflammatory pain, viseral pain, cancer pain, neuropathic pain, lower back pain, muscular sceletal, post operative pain, acute pain and migraine.

14. (New) 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide or a pharmaceutically acceptable derivative thereof.

15. (New) 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide.

16. (New) 2-(3-Chloro-4-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclopentylmethyl-amide or a pharmaceutically acceptable derivative thereof.

17. (New) 2-(3-Chloro-4-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclopentylmethyl-amide.

18. (New) A pharmaceutical composition comprising 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide or a pharmaceutically acceptable derivative thereof.

19. (New) A pharmaceutical composition comprising 2-(3-chloro-4-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclopentylmethyl-amide or a pharmaceutically acceptable derivative thereof.

20. (New) A method of treating an animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound selected from 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide and 2-(3-chloro-4-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclopentylmethyl-amide.

21. (New) The method as claimed in claim 20, wherein said animal is a human.

22. (New) The method as claimed in claim 20, wherein said condition is an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis.

23. (New) The method as claimed in claim 20, wherein the pain is selected from inflammatory pain, viseral pain, cancer pain, neuropathic pain, lower back pain, muscular sceletal, post operative pain, acute pain and migraine.



Express Mail Label No.
EV 332064093 US